Multiple myeloma cells increase Th3 cytokine response by secreting TGF-β, which causes defective Th1 and Th2 cytokine responses. Therefore, a significant suppression of the immune system is seen in multiple myeloma. Interferon-α (IFN-α) is used in the treatment of multiple myeloma due to its immunomodulatory and anti-tumoral effects. We attempted to define the characteristics of immune cytokine responses and the effects of IFN-α-2a on the immune response in multiple myeloma.
Methods
Fifteen patients with multiple myeloma and 15 healthy controls were enrolled. IFN-α-2a, 3 million units/day x 3 times/week, was administered subcutaneously to the patients for 2 weeks. Cytokines (TGF-β, IL-1, IL-2, IL-4, IL-10, IFN-γ) were assessed by the ELISA method in sera of the patients in pretreatment and posttreatment periods and in the sera of the controls.
Results
IL-2 and IL-4 levels in patients, before IFN-α-2a, were lower than the controls, whereas TGF-β levels were higher than the controls. In other words, Th3 cytokine response was increased and Th1 and Th2 cytokine responses were decreased in patients. A short course of IFN-α-2a increased IL-2 levels.
Conclusions
These findings suggest IFN-α-2a may enhance nonTh3 cytokine responses in multiple myeloma patients.
LappinM.B., CampbellJ.D.: The Thl-Th2 classification of cellular immune responses: concepts, current thinking and applications in haematological malignancy. Blood Rev, 14: 228–239, 2000.
3.
BartnesK., HannestadK.: Native IgG2a(b) is barely antigenic to major histocompatibility complex class II-restricted T cells owing to inefficient internalization by professional antigenpresenting cells. Immunology, 99: 510–522, 2000.
4.
CookG., CampbellJ.D.: Immune regulation in multiple myeloma: the host-tumour conflict. Blood Rev, 13: 151–162, 1999.
5.
FrassanitoM.A., CusmaiA., DammaccoF.: Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin Exp Immunol, 125: 190–197, 2001.
6.
RaitakariM., BrownR.D., GibsonJ., JoshuaD.E.: T cells in myeloma. Hematol Oncol, 21: 33–42, 2003.
7.
TreonS.P., RajeN., AndersonK.C.: Immunotherapeutic strategies for the treatment of plasma cell malignancies. Semin Oncol, 27: 598–613, 2000.
8.
WenY.J., MinR., TricotG., BarlogieB., YiQ.: Tumor lysatespecific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood, 99: 3280–3285, 2002.
LudwigH., FritzE.: Maintenance with interferon alpha in myeloma. In: Acute leukemias VII, Hiddemann (Eds), pp 1185–1192, Springer-Verlag, Berlin, Heidelberg, 1998.
11.
GranderD.: How does interferon-alpha exert its antitumour activity in multiple myeloma?Acta Oncol, 39: 801–805, 2000.
12.
MatsuiW., HuffC.A., ValaM., BarberJ., SmithB.D., JonesR.J.: Anti-tumour activity of interferon-alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation. Br J Haematol, 121: 251–258, 2003.
13.
ChenQ., GongB., Mahmoud-AhmedA.S., ZhouA., HsiE.D., HusseinM., AlmasanA.: Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood, 98: 2183–2192, 2001.
14.
MottaM.R., CastellaniS., RizziS., CurtiA., GubinelliF., FogliM., FerriE., CelliniC., BaccaraniM., LemoliR.M.: Generation of dendritic cells from CD 14+ monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination. Br J Haematol, 121: 240–250, 2003.
15.
DurieB.M.G., SalmonS.E.: Multiple myeloma, macroglobulinemia and monoclonal gammopathies. In: Recent Advances in Heamatology, HoffbrandA.V., BrainM.C., HirshJ. (Eds), pp 243–261, Churchill Livingstone, New York, 1977.
16.
DurieB.M.G., SalmonS.E.: A clinical staging system for multiple myeloma. Cancer, 36: 842–854, 1975.
17.
MaedaH., ShiraishiA.: TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol, 156: 73–78, 1996.
18.
CookG., CampbellJ.D., CarrC.E., BoydK.S., FranklinI.M.: Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes. J Leukoc Biol, 66: 981–988, 1999.
19.
SchwabG., SiegallC.B., AardenL.A., NeckersL.M., NordanR.P.: Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood, 77: 587–593, 1991.
20.
WestendorfJ.J., AhmannG.J., GreippP.R., WitzigT.E., LustJ.A., JelinekD.F.: Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia, 10: 866–876, 1996.
21.
CiminoG., AvvisatiG., AmadoriS., CavaM.C., GiannarelliD., Di NucciG.D., MaglioccaV., PetrucciM.T., PotiG., SgadariC.: High serum IL-2 levels are predictive of prolonged survival in multiple myeloma. Br J Haematol, 75: 373–377, 1990.
22.
StritzkeJ., ZunkelT., SteinmannJ., SchmitzN., UharekL., ZeisM.: Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin 2 in a myeloma model. Br J Haematol, 120: 27–35, 2003.
23.
MillarB.C., MillarJ.L., PowlesR.L., CatovskyD.: Interferongamma+ and interleukin-2+ T cells in peripheral blood from multiple myeloma patients in relation to disease status and maintenance therapy with interferon-alpha-2b (intron A). Br J Haematol, 98: 119–125, 1997.
24.
PorrataL.F., InwardsD.J., LacyM.Q., MarkovicS.N.: Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation. Bone Marrow Transplant, 28: 673–680, 2001.
25.
LautaV.M.: A review of the cytokine network in multiple myeloma. Cancer, 15: 2440–2452, 2003.
